New Delhi, Jun 3 (PTI) Drug maker Lupin on Monday said it has launched a generic medication used to treat or prevent bacterial infections in the US market.

The company has launched Doxycycline for Injection USP (100 single-dose vial) in the US post approvals from the US Food and Drug Administration (USFDA), the Mumbai-based drug maker said in a statement.

Also Read | Parade of Planets 2024: Six Planets of Solar System To Align in Straight Line Today, Know Time and How To Watch Rare Planetary Alignment in India.

The company's product is a generic equivalent of Pfizer Inc's Vibramycin for Injection which is indicated to reduce the development of drug-resistant bacteria.

As per the IQVIA MAT April 2024 data, Doxycycline for Injection USP had an estimated annual sale of USD 48 million in the US.

Also Read | JIPMAT 2024 Admit Card Out at exams.nta.ac.in: Hall Ticket for JIPMAT Examination on June 6 Released, Know Steps To Download.

Lupin said it has also received tentative approval from the USFDA for its abbreviated new drug application for Letermovir Tablets, 240 mg and 480 mg.

The product is the generic equivalent of Merck Sharp & Dohme LLC's Prevymis tablets (240 mg and 480 mg).

Letermovir tablets are indicated to prevent disease caused by a virus called cytomegalovirus (CMV).

As per the IQVIA MAT April 2024 data, Letermovir tablets had an estimated annual sale of USD 314 million in the US.

Shares of the company on Monday ended 0.25 per cent at Rs 1,583.95 apiece on the BSE.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)